These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24217803)

  • 21. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19.
    Requião-Moura LR; Modelli de Andrade LG; de Sandes-Freitas TV; Cristelli MP; Viana LA; Nakamura MR; Garcia VD; Manfro RC; Simão DR; Almeida RAMB; Ferreira GF; Costa KMAH; de Lima PR; Pacheco-Silva A; Charpiot IMMF; Deboni LM; Ferreira TCA; Mazzali M; Calazans CAC; Oriá RB; Tedesco-Silva H; Medina-Pestana J;
    Transplantation; 2022 Oct; 106(10):e441-e451. PubMed ID: 35765133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the nephron be spared?
    Flechner SM
    Kidney Int; 2011 Apr; 79(8):804-6. PubMed ID: 21451536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histopathologic impacts of everolimus introduction on kidney transplant recipients.
    Nakamura T; Ushigome H; Takata T; Nakao T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):630-4. PubMed ID: 25891700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
    Billing H; Burmeister G; Plotnicki L; Ahlenstiel T; Fichtner A; Sander A; Höcker B; Tönshoff B; Pape L
    Transpl Int; 2013 Sep; 26(9):903-9. PubMed ID: 23865768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
    Bozkaya G; Nart A; Uslu A; Onman T; Aykas A; Doğan M; Karaca B
    Transplant Proc; 2008; 40(1):151-5. PubMed ID: 18261573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
    Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
    Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.
    Watorek E; Szymczak M; Boratynska M; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):2967-9. PubMed ID: 21996202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
    Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
    Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
    Mulgaonkar S; Kaufman DB
    Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation.
    Korucu B; Yeter H; Guz G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Apr; 43(1):101-107. PubMed ID: 35451298
    [No Abstract]   [Full Text] [Related]  

  • 39. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors.
    Srivastava A; Muruganandham K; Vinodh PB; Singh P; Dubey D; Kapoor R; Kumar A; Sharma RK; Prasad N
    Int Urol Nephrol; 2010 Jun; 42(2):279-84. PubMed ID: 19557542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.